Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
|2||Not yet recruiting||
Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).
|3||Active, not recruiting||
Multiple Ascending Dose (MDX1105-01)
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer
† Indicates status has not been verified in more than two years